PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.
Market Cap | 164.169 Million | Shares Outstanding | 31.33 Million | Avg 30-day Volume | 655.043 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.35 |
Price to Revenue | 0.0 | Debt to Equity | 0.7233 | EBITDA | -47.724 Million |
Price to Book Value | 4.7755 | Operating Margin | 0.0 | Enterprise Value | 117.777 Million |
Current Ratio | 8.015 | EPS Growth | -0.584 | Quick Ratio | 7.67 |
1 Yr BETA | 2.1711 | 52-week High/Low | 13.65 / 3.8 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -43.3749 | Free Cash Flow to Firm (FCFF) TTM | -30.598 Million | Free Cash Flow to Equity (FCFE) TTM | -33.753 Million |
Altman Z-Score | -1.1788 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BOESGAARD LARS CHIEF FINANCIAL OFFICER |
|
0 | 2023-12-04 | 2 |
|
0 | 2023-07-14 | 1 | |
|
0 | 2023-07-14 | 1 | |
|
0 | 2023-07-14 | 1 | |
|
0 | 2023-07-14 | 1 | |
|
0 | 2023-07-14 | 1 | |
|
0 | 2023-07-14 | 1 | |
HILL MATTHEW C CHIEF FINANCIAL OFFICER |
|
161,200 | 2023-01-05 | 1 |
WOOD LAUREN CHIEF MEDICAL OFFICER |
|
110,800 | 2023-01-05 | 1 |
CONN GREGORY CHIEF SCIENTIFIC OFFICER |
|
137,200 | 2023-01-05 | 1 |
BEDU-ADDO FRANK PRESIDENT/CEO |
|
385,300 | 2023-01-05 | 1 |
BROWN SPENCER D. SENIOR VP, GENERAL COUNSEL |
|
20,400 | 2023-01-05 | 1 |
TROCHIMIUK JANETTA PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2021-09-30 | 0 |
|
798,911 | 2021-06-16 | 0 | |
VAN VOORHEES SETH CHIEF FINANCIAL OFFICER |
|
17,647 | 2021-06-15 | 0 |
KING MICHAEL N. INTERIM CFO |
|
50,000 | 2020-12-08 | 0 |
SAIK ANDREW CHIEF FINANCIAL OFFICER |
|
42,549 | 2020-02-14 | 0 |
|
0 | 2019-06-28 | 0 | |
MIDDLEKAUFF W BRADFORD SENIOR VP, GC AND SECRETARY |
|
73,770 | 2019-03-18 | 0 |
|
No longer subject to file | 2019-03-15 | 0 | |
|
678,075 | 2019-03-15 | 0 | |
|
No longer subject to file | 2019-03-15 | 0 | |
|
48,661 | 2019-03-15 | 0 | |
|
No longer subject to file | 2019-03-15 | 0 | |
LEUTHNER BRIAN A PRESIDENT AND CEO |
|
No longer subject to file | 2019-03-15 | 0 |
|
No longer subject to file | 2019-03-15 | 0 | |
WYANT ALYSSA SVP REGULATORY AFFAIRS |
|
No longer subject to file | 2018-08-15 | 0 |
MARCHIO ALBERT N II CHIEF ACCOUNTING & ADM OFFICER |
|
0 | 2018-08-14 | 0 |
FALECK HERBERT J CHIEF MEDICAL OFFICER |
|
0 | 2018-08-14 | 0 |
|
1,113,961 | 2018-03-23 | 0 | |
BRENNAN DANIEL CHIEF OPERATING OFFICER |
|
0 | 2018-03-01 | 0 |
|
0 | 2017-06-20 | 0 | |
YAMAN ALPASLAN V.P., TECHNICAL OPS. & MFG. |
|
0 | 2017-03-13 | 0 |
EINHORN ANDREW J. CHIEF FINANCIAL OFFICER |
|
126,815 | 2017-03-01 | 0 |
NEW LEAF VENTURE ASSOCIATES III, L.P. |
|
1,172,434 | 2016-06-21 | 0 |
|
0 | 2016-06-21 | 0 | |
VAISH RENU V.P., GLOBAL REG. AFFAIRS |
|
5,350 | 2016-06-16 | 0 |
|
0 | 2015-09-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-12-04 18:14:58 -0500 | 2023-12-04 | A | 200,000 | a | 200,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 21:15:05 UTC | -8.8644 | 14.1844 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 20:45:03 UTC | -8.8644 | 14.1844 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 20:15:04 UTC | -8.775 | 14.095 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 19:45:04 UTC | -8.775 | 14.095 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 19:15:04 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 18:45:03 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 18:15:03 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 17:45:03 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 17:15:04 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 16:45:04 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 16:15:04 UTC | -8.8529 | 14.1729 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 15:45:03 UTC | -8.8061 | 14.1261 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 15:15:04 UTC | -8.8061 | 14.1261 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 14:45:04 UTC | -8.8061 | 14.1261 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 14:15:04 UTC | -8.8061 | 14.1261 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 13:45:04 UTC | -6.8429 | 12.1629 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-06 13:15:04 UTC | -6.8429 | 12.1629 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-05 22:15:04 UTC | -6.5711 | 11.8911 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-05 21:45:04 UTC | -6.5711 | 11.8911 | 250000 |
PDS BIOTECHNOLOGY CORP PDSB | 2023-12-05 21:15:04 UTC | -6.5711 | 11.8911 | 250000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|